BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 14655006)

  • 1. [Drug therapy of rheumatoid arthritis].
    Arndt U; Rittmeister M; Möller B
    Orthopade; 2003 Dec; 32(12):1095-103. PubMed ID: 14655006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Evidence-based treatment of methotrexate-resistant rheumatoid arthritis. Combinations of conventional disease-modifying antirheumatic agents].
    Schnabel A; Gross WL
    Dtsch Med Wochenschr; 2003 Jan; 128(4):147-9. PubMed ID: 12589584
    [No Abstract]   [Full Text] [Related]  

  • 3. [Current concepts of pharmacotherapy in rheumatoid arthritis].
    Balabanova RM
    Vestn Ross Akad Med Nauk; 2003; (7):19-23. PubMed ID: 12934465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use.
    Proudman SM; Keen HI; Stamp LK; Lee AT; Goldblatt F; Ayres OC; Rischmueller M; James MJ; Hill CL; Caughey GE; Cleland LG
    Semin Arthritis Rheum; 2007 Oct; 37(2):99-111. PubMed ID: 17391739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and retention of combination triple disease-modifying anti-rheumatic drugs in new-onset rheumatoid arthritis.
    Cummins L; Katikireddi VS; Shankaranarayana S; Su KY; Duggan E; Videm V; Pahau H; Thomas R
    Intern Med J; 2015 Dec; 45(12):1266-73. PubMed ID: 26384029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The role of the conventional drugs in the treatment of rheumatoid arthritis].
    Fantini F
    Recenti Prog Med; 2003; 94(7-8):330-8. PubMed ID: 12868241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial.
    Rantalaiho V; Korpela M; Hannonen P; Kautiainen H; Järvenpää S; Leirisalo-Repo M; Hakala M; Puolakka K; Julkunen H; Luosujärvi R; Möttönen T;
    Arthritis Rheum; 2009 May; 60(5):1222-31. PubMed ID: 19404945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in cotherapies after initiation of disease-modifying antirheumatic drug therapy in patients with rheumatoid arthritis.
    Kawai VK; Grijalva CG; Arbogast PG; Curtis JR; Solomon DH; Delzell E; Chen L; Ouellet-Hellstrom R; Herrinton L; Liu L; Mitchel EF; Stein CM; Griffin MR
    Arthritis Care Res (Hoboken); 2011 Oct; 63(10):1415-24. PubMed ID: 22121511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and radiographic outcome of a treat-to-target strategy using methotrexate and intra-articular glucocorticoids with or without adalimumab induction: a 2-year investigator-initiated, double-blinded, randomised, controlled trial (OPERA).
    Hørslev-Petersen K; Hetland ML; Ørnbjerg LM; Junker P; Pødenphant J; Ellingsen T; Ahlquist P; Lindegaard H; Linauskas A; Schlemmer A; Dam MY; Hansen I; Lottenburger T; Ammitzbøll CG; Jørgensen A; Krintel SB; Raun J; Johansen JS; Østergaard M; Stengaard-Pedersen K;
    Ann Rheum Dis; 2016 Sep; 75(9):1645-53. PubMed ID: 26489704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Extracorporeal therapy of rheumatoid arthritis].
    Aseeva EA; Solov'ev SK; Chiklikchi AS
    Ter Arkh; 2001; 73(6):70-5. PubMed ID: 11521529
    [No Abstract]   [Full Text] [Related]  

  • 11. Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis.
    Möttönen T; Hannonen P; Korpela M; Nissilä M; Kautiainen H; Ilonen J; Laasonen L; Kaipiainen-Seppänen O; Franzen P; Helve T; Koski J; Gripenberg-Gahmberg M; Myllykangas-Luosujärvi R; Leirisalo-Repo M;
    Arthritis Rheum; 2002 Apr; 46(4):894-8. PubMed ID: 11953964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis.
    Finckh A; Bansback N; Marra CA; Anis AH; Michaud K; Lubin S; White M; Sizto S; Liang MH
    Ann Intern Med; 2009 Nov; 151(9):612-21. PubMed ID: 19884622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacotherapy of patients with (early) rheumatoid arthritis].
    Jacobs JW; Blaauw AA; Dijkmans BA; van Riel PL; Bijlsma JW
    Ned Tijdschr Geneeskd; 2000 Jan; 144(5):211-6. PubMed ID: 10682647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial.
    Verschueren P; De Cock D; Corluy L; Joos R; Langenaken C; Taelman V; Raeman F; Ravelingien I; Vandevyvere K; Lenaerts J; Geens E; Geusens P; Vanhoof J; Durnez A; Remans J; Vander Cruyssen B; Van Essche E; Sileghem A; De Brabanter G; Joly J; Meyfroidt S; Van der Elst K; Westhovens R
    Ann Rheum Dis; 2015 Jan; 74(1):27-34. PubMed ID: 25359382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leflunomide for rheumatoid arthritis.
    Drug Ther Bull; 2000 Jul; 38(7):52-4. PubMed ID: 11027115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: methotrexate as the anchor drug in 90% and new DMARD in 30% of patients.
    Sokka T; Pincus T
    J Rheumatol; 2002 Dec; 29(12):2521-4. PubMed ID: 12465145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of anti-malarials in rheumatoid arthritis--the American experience.
    Khraishi MM; Singh G
    Lupus; 1996 Jun; 5 Suppl 1():S41-4. PubMed ID: 8803910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Rational therapeutic approach in rheumatoid arthritis].
    Tłustochowicz W
    Ann Acad Med Stetin; 2006; 52 Suppl 2():5-10. PubMed ID: 17471832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Diagnosis and treatment of rheumatoid arthritis].
    Misiūniene N; Baranauskaite A
    Medicina (Kaunas); 2002; 38(1):110-6. PubMed ID: 12474726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of response to methotrexate in early DMARD naive rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial.
    Saevarsdottir S; Wallin H; Seddighzadeh M; Ernestam S; Geborek P; Petersson IF; Bratt J; van Vollenhoven RF;
    Ann Rheum Dis; 2011 Mar; 70(3):469-75. PubMed ID: 21149498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.